Nucleai, a Tel Aviv, Israel-based AI-powered spatial biology company, raised $33 million in Series B funding, this Series B financing brings Nucleai’s overall funding to close to $50 million since the company was founded four years ago.
The round was led by Section 32 and Sanofi Ventures with participation from existing investors, including Debiopharm, Fosun RZ Capital, Vertex Ventures, and Grove Ventures.
The company intends to use the funds to further develop its platform and expand its commercial footprint across biopharmaceutical companies and contract research organizations (CROs), who are applying its technology throughout translational research, clinical trials, and novel applications for drug discovery.
Andy Harrison, Managing Partner at Section 32, and Cris De Luca, Global Head, Digital Investments at Sanofi Ventures, will join Nucleai’s Board of Directors. Section 32 Managing Partner Michael Pellini, MD, will join Nucleai’s Board as an observer.
Company: Nucleai Inc.
Round: Series B
Funding Month: March 2022
Lead Investors: Section 32 and Sanofi Ventures
Additional Investors: Debiopharm, Fosun RZ Capital, Vertex Ventures, and Grove Ventures
Company Website: https://nucleai.ai/
Software Category: AI-powered Spatial Biology
About the Company: Led by CEO Avi Veidman, Nucleai provides pharmaceutical companies, contract research organizations, and diagnostics laboratories with an AI platform to improve clinical trials and clinical decision-making. The company is working with leading pharmaceutical companies to harness spatial biology for new drug development, clinical trials, and clinical treatment decisions. The platform is leveraged for retrospective and prospective patient stratification analysis in clinical trials, driving improvement of the probability of success and improved patient outcomes. Nucleai delivers a comprehensive solution that brings the computational power and scales needed to discover novel biomarkers, predicts patient response with higher-quality predictive biomarkers, identifies new targets, and develops the next generation of pathology-based companion diagnostics.